[Treatment of asthenic syndrome in patients with chronic brain ischemia: results of the non-interventional observational program TRIUMPH].

Abstract

OBJECTIVE:

To assess the severity of asthenic syndrome (AS) in chronic brain ischemia (CBI) in primary health care settings.

MATERIAL AND METHODS:

The study included 1170 patients with brain ischemia, aged 45-65 years, treated with phenotropil in dose 100 mg during 2 and 3 months. Clinical examination and MFI-20 subscales were administered. RESULTS AND СONCLUSION: The high incidence of asthenic syndrome was observed across all MFI-20 subscales. The decrease in asthenic syndrome severity was significant already in the end of the first month of treatment with phenotropil. Such dynamics maintained to the end of the second and third month of treatment. More than 2-fold decrease in the severity of asthenia symptoms was achieved in all subgroups 3 months after treatment. More rapid and apparent decrease in asthenic syndrome was observed in younger patients.

• Authors: A I Fedin, É Iu Solov'eva, O P Mironova, A V Fedotova
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 114 Issue 12 Pg. 104-111 ( 2014) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 25726789 (Publication Type: English Abstract, Journal Article, Observational Study)

Chemical References

• 4-phenylpiracetam
• Piracetam

Topics

• Aged
• Aged, 80 and over
• Asthenia (drug therapy, etiology)
• Brain Ischemia (complications)
• Chronic Disease
• Female
• Humans
• Male
• Middle Aged
• Neurasthenia (drug therapy, etiology)
• Piracetam (administration & dosage, analogs & derivatives, therapeutic use)
• Syndrome
• Treatment Outcome